CClinicalTrials.gg
CompletedNCT03815227ACCAMBUUpdated May 6, 2022

Outpatient Birth: Pilot Study

An interventional study of Outpatient birth in Outpatient Birth, sponsored by Centre Hospitalier Régional Metz-Thionville. Completed at 1 site in France. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2022-05-06.

Sponsored by Centre Hospitalier Régional Metz-Thionville · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The diminution of the average length stay (ALS) in French maternity is a clear evolution, the objective of the draft law on social security is to reduce the ALS to equal other OECD countries. The over-medicalization of maternal health raises the question of relevant and iatrogeny of Professional practices. Furthermore, pregnant woman, future parents expressed their wish for an individual support and more physiological respectful. A more-effective Professional coordination is expected where the midwife is a major player.

Read the detailed description

The aim of the study is to identify and evaluate an outpatient birth path during the first 24 hours after the birth.

02

Conditions studied

  • Outpatient Birth
03

In context

Lead sponsor

Centre Hospitalier Régional Metz-Thionville is the lead sponsor of 118 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • With no multiple pregnancy, of less than 20 weeks of gestation
  • With a BMI between 17,5 and 35 kg/m²
  • is able to understand research's informations
  • affiliated member of the social security system
  • Have given an informed consent

Exclusion criteria

Exclusion Criteria:

  • With psychological vulnerability, social vulnerability, addictions and high dependency
  • With an unbalanced chronic pathology or susceptible to contraindicated a physiologic birth
  • With history of caesarean, foeto-maternal incompatibility, gestational hypertension, pre-eclampsia, HELLP syndrome or retro-placental hematoma, sphincter tear
  • With history of birth with perinatal asphyxia and sequelae or an unexplained perinatal death
  • With history of puerperal psychosis
  • Under guardianship
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Outpatient birth

    Maternity out the same date or the next day of the birth

    Other: Outpatient birth

Interventions

  • OtherOutpatient birth

    Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife

06

What researchers measure

Primary outcomes

  1. Output rate

    Output rate within 24 hours of birth

    Time frame: Day 1

07

Study locations

1 site
  • CHR Metz Thionville
    Thionville, Moselle 57100, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03815227
Lead sponsor
Centre Hospitalier Régional Metz-Thionville
Responsible party
Sponsor
First posted
Jan 24, 2019
Start date
Jan 31, 2019
Primary completion
Jun 30, 2021
Completion
Sep 27, 2021
Last update
May 6, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion